These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37804699)

  • 1. Synthesis by diastereomeric resolution, biochemical evaluation and molecular modelling of chiral 3-hydroxyl b-lactam microtubule-targeting agents for the treatment of triple negative breast and chemoresistant colorectal cancers.
    McLoughlin EC; Twamley B; O'Brien JE; Hannon Barroeta P; Zisterer DM; Meegan MJ; O'Boyle NM
    Bioorg Chem; 2023 Dec; 141():106877. PubMed ID: 37804699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells.
    Malebari AM; Fayne D; Nathwani SM; O'Connell F; Noorani S; Twamley B; O'Boyle NM; O'Sullivan J; Zisterer DM; Meegan MJ
    Eur J Med Chem; 2020 Mar; 189():112050. PubMed ID: 31954879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, Characterisation and Mechanism of Action of Anticancer 3-Fluoroazetidin-2-ones.
    Malebari AM; Duffy Morales G; Twamley B; Fayne D; Khan MF; McLoughlin EC; O'Boyle NM; Zisterer DM; Meegan MJ
    Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Antiproliferative Evaluation of 3-Chloroazetidin-2-ones with Antimitotic Activity: Heterocyclic Bridged Analogues of Combretastatin A-4.
    Malebari AM; Wang S; Greene TF; O'Boyle NM; Fayne D; Khan MF; Nathwani SM; Twamley B; McCabe T; Zisterer DM; Meegan MJ
    Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells.
    Wang S; Malebari AM; Greene TF; Kandwal S; Fayne D; Nathwani SM; Zisterer DM; Twamley B; O'Boyle NM; Meegan MJ
    Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Vinylazetidin-2-Ones: Synthesis, Antiproliferative and Tubulin Destabilizing Activity in MCF-7 and MDA-MB-231 Breast Cancer Cells.
    Wang S; Malebari AM; Greene TF; O'Boyle NM; Fayne D; Nathwani SM; Twamley B; McCabe T; Keely NO; Zisterer DM; Meegan MJ
    Pharmaceuticals (Basel); 2019 Apr; 12(2):. PubMed ID: 30979033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones.
    O'Boyle NM; Greene LM; Bergin O; Fichet JB; McCabe T; Lloyd DG; Zisterer DM; Meegan MJ
    Bioorg Med Chem; 2011 Apr; 19(7):2306-25. PubMed ID: 21397510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, biological evaluation and cocrystal structures with tubulin of chiral β-lactam bridged combretastatin A-4 analogues as potent antitumor agents.
    Zhou P; Liang Y; Zhang H; Jiang H; Feng K; Xu P; Wang J; Wang X; Ding K; Luo C; Liu M; Wang Y
    Eur J Med Chem; 2018 Jan; 144():817-842. PubMed ID: 29306206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells.
    Malebari AM; Greene LM; Nathwani SM; Fayne D; O'Boyle NM; Wang S; Twamley B; Zisterer DM; Meegan MJ
    Eur J Med Chem; 2017 Apr; 130():261-285. PubMed ID: 28254699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of 2D EXSY and qNMR Spectroscopy for Diastereomeric Excess Determination Following Chiral Resolution of β-Lactams.
    McLoughlin EC; O'Brien JE; Trujillo C; Meegan MJ; O'Boyle NM
    ChemistryOpen; 2023 Jun; 12(6):e202200119. PubMed ID: 35876400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand.
    O'Boyle NM; Pollock JK; Carr M; Knox AJ; Nathwani SM; Wang S; Caboni L; Zisterer DM; Meegan MJ
    J Med Chem; 2014 Nov; 57(22):9370-82. PubMed ID: 25369367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.
    Greene LM; Nathwani SM; Bright SA; Fayne D; Croke A; Gagliardi M; McElligott AM; O'Connor L; Carr M; Keely NO; O'Boyle NM; Carroll P; Sarkadi B; Conneally E; Lloyd DG; Lawler M; Meegan MJ; Zisterer DM
    J Pharmacol Exp Ther; 2010 Nov; 335(2):302-13. PubMed ID: 20699436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optically active 1,3,4,4-tetrasubstituted β-lactams: synthesis and evaluation as tumor cell growth inhibitors.
    Pérez-Faginas P; Aranda MT; García-López MT; Francesch A; Cuevas C; González-Muñiz R
    Eur J Med Chem; 2011 Oct; 46(10):5108-19. PubMed ID: 21885166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of antiproliferative microtubule-destabilising combretastatin A-4 piperazine conjugates.
    O'Boyle NM; Ana G; Kelly PM; Nathwani SM; Noorani S; Fayne D; Bright SA; Twamley B; Zisterer DM; Meegan MJ
    Org Biomol Chem; 2019 Jun; 17(25):6184-6200. PubMed ID: 31173031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.
    Carr M; Greene LM; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
    Eur J Med Chem; 2010 Dec; 45(12):5752-66. PubMed ID: 20933304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships OF N-methylthiolated beta-lactam antibiotics with C3 substitutions and their selective induction of apoptosis in human cancer cells.
    Kuhn DJ; Wang Y; Minic V; Coates C; Reddy GS; Daniel KG; Shim JY; Chen D; Landis-Piwowar KR; Miller FR; Turos E; Dou QP
    Front Biosci; 2005 May; 10():1183-90. PubMed ID: 15769617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent Antitumor Activities and Structure Basis of the Chiral β-Lactam Bridged Analogue of Combretastatin A-4 Binding to Tubulin.
    Zhou P; Liu Y; Zhou L; Zhu K; Feng K; Zhang H; Liang Y; Jiang H; Luo C; Liu M; Wang Y
    J Med Chem; 2016 Nov; 59(22):10329-10334. PubMed ID: 27805821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents.
    Greene TF; Wang S; Greene LM; Nathwani SM; Pollock JK; Malebari AM; McCabe T; Twamley B; O'Boyle NM; Zisterer DM; Meegan MJ
    J Med Chem; 2016 Jan; 59(1):90-113. PubMed ID: 26680364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereochemical preference toward oncotarget: Design, synthesis and in vitro anticancer evaluation of diastereomeric β-lactams.
    Olazarán-Santibáñez F; Bandyopadhyay D; Carranza-Rosales P; Rivera G; Balderas-Rentería I
    Oncotarget; 2017 Jun; 8(23):37773-37782. PubMed ID: 28562328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting β-lactam combretastatins.
    O'Boyle NM; Greene LM; Keely NO; Wang S; Cotter TS; Zisterer DM; Meegan MJ
    Eur J Med Chem; 2013 Apr; 62():705-21. PubMed ID: 23454513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.